Fig. 1 · Structure

Documents & Downloads

Aniracetam

Cat. No. A10078 CAS 72432-10-1

AMPA receptor positive allosteric modulator

Aniracetam is an ampakine and nootropic of the racetam chemical class purported to be considerably more potent than piracetam.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Aniracetam binds at the GluR2 ligand-binding domain dimer interface near the clamshell hinge. Its fluorowillardiine-bound cocrystal supports a structural model in which the modulator favors the closed ligand-binding cleft. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
AMPA Receptor  

Aniracetam Research Summary

This section summarizes 2 in vitro studies of Aniracetam from 1 published reference.

Aniracetam In Vitro Studies

In HEK 293 outside-out patches expressing GluR2 flop, 5 mM aniracetam slowed deactivation after a 1 ms pulse of 3 mM quisqualate. Its additional effect on desensitization during a 500 ms pulse was small in this system. [1]

Aniracetam binding in the GluR2 ligand-binding core

Biochemical assay · Purified rat GluR2 flop-derived S1S2J ligand-binding core with fluorowillardiine. [1]

The cocrystal places aniracetam in a single site at the dimer interface near the clamshell hinge. Two modeled orientations each have occupancy 0.5; these represent one bound molecule per interface, rather than two simultaneously bound molecules.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Ani/fluorowillardiine cocrystal diffraction resolutionResolution 1.65 Å[1]
Location of aniracetam in the receptor complexStructural localization Dimer interface, adjacent to the clamshell hinge[1]

Literature-Reported Treatment Conditions

Treatment concentration
10 mM aniracetam; 5 mM fluorowillardiine added before crystallization
Method
Cocrystallization of purified ligand-binding core; diffraction and structural refinement.
Co-treatment
Fluorowillardiine is the agonist in the aniracetam complex.
Reported limits
These concentrations are crystallization inputs, not affinity or potency values. Crystallization time is not specified in the acquired methods.
Methods and source locations

Compound reported in the paper: Aniracetam; Compound label in the paper: Ani

Evidence for the named parent compound in the specified receptor systems; no supplier-lot validation.

Materials and Methods: Materials, Crystallization and measurement of diffraction data, Structure determination; Results: Structures of Ani/FW and CX/Quis complexes; Tables 1–2; Figures 1B, 2A, 3A–B

Ani/fluorowillardiine cocrystal diffraction resolution: X-ray crystallography — Results: Structures of Ani/FW and CX/Quis complexes; Tables 1–2

Location of aniracetam in the receptor complex: Electron density and structural model — Results: Structures of Ani/FW and CX/Quis complexes; Figures 2A and 3A–B

Aniracetam modulation of recombinant GluR2 currents

Cell-based study · Outside-out patches from transiently transfected HEK 293 cells expressing GluR2 flop. [1]

At 5 mM, aniracetam slowed deactivation following a brief quisqualate pulse. Its additional effect on desensitization was small in this recombinant system; the pronounced desensitization effect of CX614 cannot be assigned to aniracetam.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Decay of current after agonist removalQualitative kinetic effect Slower deactivation with aniracetam than no-drug control[1]
Current decay during sustained agonist applicationQualitative kinetic effect Little additional effect on desensitization[1]

Literature-Reported Treatment Conditions

Treatment concentration
5 mM aniracetam; 3 mM quisqualate
Exposure duration
Agonist pulses: 1 ms for deactivation and 500 ms for desensitization.
Method
Rapid solution exchange, outside-out patch clamp at −60 mV; agonist responses compared with drug-free baseline.
Vehicle
Baseline perfusion vehicle contained 1% DMSO; the methods describe corresponding configurations for aniracetam and comparator modulators.
Co-treatment
Quisqualate as receptor agonist; CX614 and cyclothiazide were separate comparator conditions.
Reported limits
Figure 1 does not provide aniracetam-specific replicate counts or tabulated kinetic estimates. No IC50/EC50 is inferred from this single concentration.
Methods and source locations

Compound reported in the paper: Aniracetam; Compound label in the paper: Ani

Evidence for the named parent compound in the specified receptor systems; no supplier-lot validation.

Materials and Methods: Materials, Transient transfections, Outside-out patch recordings, Analysis of rapid responses; Results: Modulation of deactivation; Figure 1A

Decay of current after agonist removal: Patch clamp after a 1 ms pulse of 3 mM quisqualate — Results: Modulation of deactivation; Figure 1A

Current decay during sustained agonist application: Patch clamp during a 500 ms pulse of 3 mM quisqualate — Results: Modulation of deactivation; Figure 1A

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 72432-10-1
Applications AMPA receptor positive allosteric modulator
Formula C12H13NO3
Molecular Weight 219.24
SMILES
COC1=CC=C(C=C1)C(=O)N2CCCC2=O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 38 mg/mL (173.32 mM)
Water Insoluble
Ethanol 15 mg/mL (68.42 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Aniracetam Research References

  1. [1] Rongsheng Jin, Suzanne Clark, Autumn M. Weeks, et al. Mechanism of Positive Allosteric Modulators Acting on AMPA Receptors Journal of Neuroscience (2005). PMID: 16192394 DOI: 10.1523/JNEUROSCI.2567-05.2005 Source material

Added to your cart

View Cart Checkout
Loading...